SEARCH

SEARCH BY CITATION

References

  • 1
    National Center for Health Statistics (2001) Health, United States, 2000 National Center for Health Statistics Washington, DC.
  • 2
    National Center for Health Statistics (2001) Prevalence of Overweight among Children and Adolescents: United States, 1999 National Center for Health Statistics Washington, DC.
  • 3
    Must, A., Strauss, R. S. (1999) Risks and consequences of childhood and adolescent obesity. Int J Obes Relat Metab Disord 23: (Suppl 2), S2S11.
  • 4
    Maffeis, C. (2000) Aetiology of overweight and obesity in children and adolescents. Eur J Pediatr 159: (Suppl 1), S35S44.
  • 5
    Jeffery, R. W., Drewnowski, A., Epstein, L. H., et al. (2000) Long-term maintenance of weight loss: current status. Health Psychol 19: 516.
  • 6
    Haddock, C., Shadish, W., Klesges, R., Stein, R. (1994) Treatments for childhood and adolescent obesity. Ann Behav Med 16: 235244.
  • 7
    DeWolfe, J. A., Jack, E. (1984) Weight control in adolescent girls: a comparison of the effectiveness of three approaches to follow-up. J Sch Health 54: 347349.
  • 8
    Mellin, L. M., Slinkard, L. A., Irwin, C. E. Jr (1987) Adolescent obesity intervention: validation of the SHAPEDOWN program. J Am Diet Assoc 87: 333338.
  • 9
    Hoerr, S. L., Nelson, R. A., Essex-Sorlie, D. (1988) Treatment and follow-up of obesity in adolescent girls. J Adolesc Health Care 9: 2837.
  • 10
    Wadden, T. A., Stunkard, A. J., Rich, L., Rubin, C. J., Sweidel, G., McKinney, S. (1990) Obesity in black adolescent girls: a controlled clinical trial of treatment by diet, behavior modification, and parental support. Pediatrics 85: 345352.
  • 11
    Thomas-Dobersen, D. A., Butler-Simon, N., Fleshner, M. (1993) Evaluation of a weight management intervention program in adolescents with insulin-dependent diabetes mellitus. J Am Diet Assoc 93: 535540.
  • 12
    Gately, P. J., Cooke, C. B., Butterly, R. J., Mackreth, P., Carroll, S. (2000) The effects of a children's summer camp programme on weight loss, with a 10 month follow-up. Int J Obes Relat Metab Disord 24: 14451452.
  • 13
    Rocchini, A. P., Katch, V., Schork, A., Kelch, R. P. (1987) Insulin and blood pressure during weight loss in obese adolescents. Hypertension 10: 267273.
  • 14
    Becque, M. D., Katch, V. L., Rocchini, A. P., Marks, C. R., Moorehead, C. (1988) Coronary risk incidence of obese adolescents: reduction by exercise plus diet intervention. Pediatrics 81: 605612.
  • 15
    Mittendorfer, B., Ostlund, R. J., Patterson, B., Klein, S. (2001) Orlistat inhibits dietary cholesterol absorption. Obes Res 9: 599604.
  • 16
    Guerciolini, R. (1997) Mode of action of orlistat. Int J Obes Relat Metab Disord 21: (Suppl 3), S12S23.
  • 17
    Rossner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G. (2000) Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 8: 4961.
  • 18
    Davidson, M. H., Hauptman, J., DiGirolamo, M., et al. (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281: 235242.
  • 19
    Drent, M. L., van der Veen, E. A. (1995) First clinical studies with orlistat: a short review. Obes Res 3: (Suppl 4), 623S625S.
  • 20
    Finer, N., James, W. P., Kopelman, P. G., Lean, M. E., Williams, G. (2000) One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 24: 306313.
  • 21
    Hauptman, J., Lucas, C., Boldrin, M. N., Collins, H., Segal, K. R. (2000) Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 9: 160167.
  • 22
    Hollander, P. A., Elbein, S. C., Hirsch, I. B., et al. (1998) Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21: 12881294.
  • 23
    James, W. P., Avenell, A., Broom, J., Whitehead, J. (1997) A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord 21: (Suppl 3), S24S30.
  • 24
    Karhunen, L., Franssila-Kallunki, A., Rissanen, P., et al. (2000) Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord 24: 15671572.
  • 25
    Lindgarde, F. (2000) The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 248: 245254.
  • 26
    Sjöström, L., Rissanen, A., Andersen, T., et al. (1998) Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352: 167172.
  • 27
    van Gaal, L. F., Broom, J. I., Enzi, G., Toplak, H. (1998) Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 54: 125132.
  • 28
    Zavoral, J. H. (1998) Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 16: 20132017.
  • 29
    Lohman, T., Roche, A., Martorell, R. (1988) Anthropometric Standardization Reference Manual 4157, 51–69 Human Kinetics Books Champagne, IL.
  • 30
    Dempster, P., Aitkens, S. (1995) A new air displacement method for the determination of human body composition. Med Sci Sports Exerc 27: 16921697.
  • 31
    McCrory, M. A., Gomez, T. D., Bernauer, E. M., Mole, P. A. (1995) Evaluation of a new air displacement plethysmograph for measuring human body composition. Med Sci Sports Exerc 27: 16861691.
  • 32
    Levenhagen, D. K., Borel, M. J., Welch, D. C., et al. (1999) A comparison of air displacement plethysmography with three other techniques to determine body fat in healthy adults. JPEN J Parenter Enteral Nutr 23: 293299.
  • 33
    Biaggi, R. R., Vollman, M. W., Nies, M. A., et al. (1999) Comparison of air-displacement plethysmography with hydrostatic weighing and bioelectrical impedance analysis for the assessment of body composition in healthy adults. Am J Clin Nutr 69: 898903.
  • 34
    Lockner, D. W., Heyward, V. H., Baumgartner, R. N., Jenkins, K. A. (2000) Comparison of air-displacement plethysmography, hydrodensitometry, and dual X-ray absorptiometry for assessing body composition of children 10 to 18 years of age. Ann NY Acad Sci 904: 7278.
  • 35
    Siri, W. (1961) Body composition from fluid spaces and density: analysis of methods. Brozek, J. Honschel, A. eds. Techniques for Measuring Body Composition National Academy of Sciences/National Research Council Washington, DC. 223224.
  • 36
    Nixon, D. E., Moyer, T. P., Johnson, P., et al. (1986) Routine measurement of calcium, magnesium, copper, zinc, and iron in urine and serum by inductively coupled plasma emission spectroscopy. Clin Chem 32: 16601665.
  • 37
    McClean, S. W., Ruddel, M. E., Gross, E. G., DeGiovanna, J. J., Peck, G. L. (1982) Liquid-chromatographic assay for retinol (vitamin A) and retinol analogs in therapeutic trials. Clin Chem 28: 693696.
  • 38
    Hollis, B. W., Kamerud, J. Q., Selvaag, S. R., Lorenz, J. D., Napoli, J. L. (1993) Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 39: 529533.
  • 39
    Davidson, K. W., Sadowski, J. A. (1997) Determination of vitamin K compounds in plasma or serum by high-performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection. Methods Enzymol 282: 408421.
  • 40
    Jansson, L., Nilsson, B., Lindgren, R. (1980) Quantitation of serum tocopherols by high-performance liquid chromatography with fluorescence detection. J Chromatogr 181: 242247.
  • 41
    DiSanto, A. R., Wagner, J. G. (1972) Pharmacokinetics of highly ionized drugs. II. Methylene blue-absorption, metabolism, and excretion in man and dog after oral administration. J Pharm Sci 61: 10861090.
  • 42
    Bergman, R. N. (1989) Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 38: 15121527.
  • 43
    Boden, G., Reichard, G., Hoeldtke, R., Rezvzni, I., Owen, O. (1981) Severe insulin-induced hypoglycemia experienced by patients with type 2 diabetes associated with deficiencies in the release of counterregulatory hormones. N Engl J Med 305: 12001205.
  • 44
    Hepburn, D., MacLeod, K., Pell, A., Scougal, I., Frier, B. (1993) Frequency and symptoms of hypoglycemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 10: 231237.
  • 45
    Corso, D. M., Pucino, F., DeLeo, J. M., Calis, K. A., Gallelli, J. F. (1992) Development of a questionnaire for detecting potential adverse drug reactions. Ann Pharmacother 26: 890896.
  • 46
    Clemens, T. L., Adams, J. S., Henderson, S. L., Holick, M. F. (1982) Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1: 7476.
  • 47
    Matsuoka, L. Y., Wortsman, J., Haddad, J. G., Kolm, P., Hollis, B. W. (1991) Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol 127: 536538.
  • 48
    Matsuoka, L. Y., Wortsman, J., Chen, T. C., Holick, M. F. (1995) Compensation for the interracial variance in the cutaneous synthesis of vitamin D. J Lab Clin Med 126: 452457.
  • 49
    Drent, M. L., Popp-Snijders, C., Ader, H. J., Jansen, J. B., van der Veen, E. A. (1995) Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects. Obes Res 3: 573581.
  • 50
    Beermann, B., Melander, H., Sawe, J., Ulleryd, C., Dahlqvist, R. (2001) Incorrect use and limited weight reduction of orlistat (Xeical) in clinical practice. A cohort study. Eur J Clin Pharmacol 57: 309311.
  • 51
    Wadden, T. A., van Itallie, T. B., Blackburn, G. L. (1990) Responsible and irresponsible use of very-low-calorie diets in the treatment of obesity. JAMA 263: 8385.
  • 52
    Kay, J. P., Alemzadeh, R., Langley, G., D'Angelo, L., Smith, P., Holshouser, S. (2001) Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50: 14571461.
  • 53
    Freemark, M., Bursey, D. (2001) The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 107: E55.
  • 54
    Heck, A. M., Yanovski, J. A., Calis, K. A. (2000) Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 20: 270279.
  • 55
    Tonstad, S., Pometta, D., Erkelens, D. W., et al. (1994) The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 46: 405410.
  • 56
    Heymsfield, S. B., Segal, K. R., Hauptman, J., et al. (2000) Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 160: 13211326.